MiNK Therapeutics, Inc.
INKT Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$10.71
KIRA · Stoqly’s AI analyst, in plain words
- MiNK Therapeutics, Inc. had $0.2M of revenue in fiscal 2025, up 4.4% on the year before.
- Its operating margin was −7,015.6%, down 475.4 pts: of every 100 in sales, about −7,016 is left after running the business.
- MiNK Therapeutics, Inc. lost $12.5M in fiscal 2025.
Market cap
$53.8M
P/E
—
Revenue
$0.2M
Net income
−$12.5M
Free cash flow
—
Operating margin
−7,015.6%
MiNK Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+4.4%
Only a little. Sales grew 4.4% last year.
Does it make a profit?
−6,933.6%
No. It lost money last year.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What MiNK Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 31, 2026
- Legal name
- MiNK Therapeutics, Inc.
- CIK
- 0001840229
MiNK Therapeutics, Inc. · INKT
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | −$2.4M | $0.3M | $0.5M | $0.2M | $0.2M |
| Revenue growth | — | — | 82.9% | −62.7% | 4.4% |
| Net interest income | −$2.4M | $0.3M | $0.5M | $0.2M | $0.2M |
| Operating margin | 1,166.3% | −12,218.4% | −4,947.4% | −6,540.2% | −7,015.6% |
| Net income | −$30.2M | −$28.0M | −$22.5M | −$10.8M | −$12.5M |
| Net margin | 1,242.5% | −11,050.6% | −4,847.4% | −6,248.4% | −6,933.6% |
| Diluted EPS | −$1.16 | −$0.83 | −$6.54 | −$2.86 | −$2.93 |
| Cash | |||||
| Cash from operations | −$12.8M | −$18.9M | −$15.8M | −$9.6M | −$5.9M |
| Capital expenditure | $0.2M | $0.3M | $0.1M | — | — |
| Free cash flow | −$13.1M | −$19.1M | −$15.8M | — | — |
| FCF margin | 537.8% | −7,547.1% | −3,418.1% | — | — |
| Share count change | 8.0% | 29.4% | −89.8% | 9.8% | 13.2% |
| Debt and strength | |||||
| Cash and short-term investments | $38.9M | $19.6M | $3.4M | $4.6M | $13.4M |
| Shareholders' equity | $23.8M | −$0.4M | −$18.1M | −$19.6M | −$14.2M |
| Current ratio | 2.4x | 1.6x | 0.3x | 0.7x | 1.1x |
| Interest coverage | −11.7x | — | — | — | — |
| Returns and quality | |||||
| Return on equity | — | −239.5% | — | — | — |
| Return on tangible equity | −127.1% | — | — | — | — |
| Piotroski F-score | — | 2 | 3 | 3 | 3 |
| Altman Z'' | −6.2 | −24.2 | −141.4 | −98.5 | −42.0 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.1M
2 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
MiNK Therapeutics, Inc. · INKT
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $10.71 a share, the company is worth $53.8M.
Source: SEC EDGAR XBRL filings (CIK 0001840229). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.